<DOC>
	<DOCNO>NCT00002521</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Bone marrow peripheral stem cell transplantation may allow doctor give high dos chemotherapy kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy cyclophosphamide , etoposide cisplatin follow bone marrow and/or peripheral stem cell transplantation patient relapse refractory intermediate- high-grade non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Bone Marrow and/or Peripheral Stem Cell Transplantation Treating Patients With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine curative potential high-dose cyclophosphamide , etoposide , cisplatin ( CEP ) syngeneic autologous bone marrow and/or autologous peripheral blood stem cell rescue patient relapse refractory , stage I-IV , intermediate- high-grade non-Hodgkin 's lymphoma . - Determine overall response rate survival patient treat regimen . - Determine toxic effect regimen patient . - Determine difference rate engraftment , response , survival patient treat bone marrow v peripheral blood stem cell transplantation . - Determine response rate survival patient treat consolidative radiotherapy recovery transplantation . - Determine toxic effect consolidative radiotherapy recovery transplantation patient . OUTLINE : Syngeneic autologous bone marrow and/or autologous peripheral blood stem cell ( PBSC ) harvest . Syngeneic bone marrow transplantation prefer patient qualify identical twin donor . Patients without syngeneic donor history lymphomatous involvement bone marrow profoundly hypocellular undergo harvest PBSC alone . Patients without syngeneic donor history lymphomatous involvement bone marrow undergo harvest autologous bone marrow PBSC . Patients receive condition comprise cyclophosphamide IV 1 hour day -6 -3 etoposide IV 1 hour every 12 hour cisplatin IV continuously day -6 -4 . Bone marrow and/or PBSC infuse day 0 . ( Patients require 25 bag stem cell receive bone marrow transplantation day 0 PBSC transplantation day 1 . ) After recovery transplantation , eligible patient receive consolidative radiotherapy site prior bulk disease ( great 5 cm ) present time transplantation site disease present time transplantation . Patients follow 3 , 6 , 12 month annually thereafter . PROJECTED ACCRUAL : A maximum 30 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven relapsed refractory , stage IIV , intermediate highgrade nonHodgkin 's lymphoma Eligible subtypes : Diffuse small cleave cell Diffuse mix ( small large cell ) Diffuse large cell Large cell immunoblastic Lymphoblastic Small noncleaved cell Highgrade histology patient first consider Protocol TUHSC1520 Must chemosensitive disease , define 1 follow condition : Response initial chemotherapy without obtain complete response ( CR ) ( refractory lymphoma ) Relapse chemotherapyinduced CR tumor volume reduce least 25 % 1 month completion 13 course salvage chemotherapy ( chemosensitive relapse ) No chemoresistant disease , define following condition : Unresponsive progressive disease initial chemotherapy Relapse chemotherapyinduced CR tumor volume reduce least 25 % completion 13 course salvage chemotherapy ( chemoresistant relapse ) No CNS involvement lymphoma Syngeneic bone marrow transplantation offer patient consent identical twin donor NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Age : 15 60 ( physically fit patient age 70 may consider ) Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 2.0 mg/dL AST ALT persistently great 2 time normal Renal : Creatinine le 1.8 mg/dL Cardiovascular : Cardiac ejection fraction least 45 % Pulmonary : DLCO , FEV_1 , FVC least 50 % predict Resting pO_2 least 70 mm Hg Other : HIV negative No concurrent disease would limit life expectancy No active infection No severe neurologic emotional disorder Not pregnant Fertile patient must use effective contraception Adequate psychological support available PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>stage I adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage I adult lymphoblastic lymphoma</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
</DOC>